Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (NCT07359872) titled 'Relaxin Therapy for Atrial Fibrillation' on Jan. 20.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Deeptankar DeMazumder
Condition:
Atrial Fibrillation (AF)
Arrhythmia
Oxidative Stress
Stroke
Major Cardiovascular Event
Heart Failure
Catheter Ablation
Ablation of Atrial Fibrillation
Intervention:
Drug: Relaxin
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: January 1, 2027
Target Sample...